Medication info
Trevel Tablet 80/5/10 mg

Trevel Tablet 80/5/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablets
Packaging
30 tablets (10 tablets x 3)/PTP
Approval status
Active

MFDS item code 201802585 · Approved 2018.06.20 · Insurance code 693902850

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate medicines, switching to this medicine (a combination product containing the same amount of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before starting the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5mg: For patients whose blood pressure is not adequately controlled with amlodipine 5mg or telmisartan 40mg. - 80/5mg: For patients whose blood pressure is not adequately controlled with amlodipine 5mg or this medicine 40/5mg. - 40/10mg: For patients whose blood pressure is not adequately controlled with amlodipine 10mg. - 80/10mg: For patients whose blood pressure is not adequately controlled with amlodipine 10mg or this medicine 40/10mg. ◦ Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40mg in patients with mild or moderate hepatic impairment. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20mg daily. 2. Older patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of the 40mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled even after treatment with telmisartan and amlodipine combination, and for patients with hypercholesterolemia and dyslipidemia who cannot control their condition with dietary changes and exercise alone. Telmisartan and amlodipine effectively lower blood pressure and improve hypertensive symptoms, while rosuvastatin helps treat hypercholesterolemia and reduce the risk of cardiovascular disease. Additionally, rosuvastatin helps slow the progression of atherosclerosis and reduces the risk of stroke, myocardial infarction, and recurrence after vascular reintervention in high-risk patients. Therefore, this medication is used to manage both blood pressure and lipid levels simultaneously to improve heart and vascular health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate medicines, switching to this medicine (a combination product containing the same amount of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before starting the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5mg: For patients whose blood pressure is not adequately controlled with amlodipine 5mg or telmisartan 40mg. - 80/5mg: For patients whose blood pressure is not adequately controlled with amlodipine 5mg or this medicine 40/5mg. - 40/10mg: For patients whose blood pressure is not adequately controlled with amlodipine 10mg. - 80/10mg: For patients whose blood pressure is not adequately controlled with amlodipine 10mg or this medicine 40/10mg. ◦ Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40mg in patients with mild or moderate hepatic impairment. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20mg daily. 2. Older patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of the 40mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication can cause serious harm to the fetus and newborn during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Those with hypersensitivity to any of the active ingredients or components, specific hereditary angioedema patients, pregnant women or women of childbearing potential, patients with severe liver dysfunction, etc. should not take this medication. Severe renal impairment, patients with diabetes and renal impairment, patients with myopathy, and cases where this medication is used in conjunction with certain other medications also require caution or are contraindicated. Elderly patients, those with hypotension, liver impairment, and hyperkalemia require special caution when taking this medication, and liver function and muscle condition should be monitored regularly. This medication may cause muscle pain, weakness, or cramps; if such symptoms occur, consult a doctor immediately. Adverse reactions such as liver dysfunction, allergic reactions, low blood pressure, and edema may occur, so report symptoms to medical personnel. There may be interactions with other medications, so inform healthcare providers of any other medications being taken, especially diuretics, potassium-sparing agents, and immunosuppressants. Women who may become pregnant should use appropriate contraception, and those who are breastfeeding should either refrain from taking this medication or discontinue breastfeeding. The safety and efficacy of this medication have not been adequately verified for children, so it is not recommended for use in this population. In case of overdose, symptoms such as hypotension, dizziness, and renal function abnormalities may occur, necessitating immediate medical attention. During the use of this medication, be cautious of dizziness or drowsiness while driving or operating dangerous machinery. Store this medication out of the reach of children, and ensure it is not transferred to another container.

Side effects

Viral upper respiratory tract inflammation, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, hiatal hernia, infection, fungal infection, abscess, otitis media, headache, dizziness, orthostatic hypotension, lumbago, vascular edema, erectile dysfunction, increased sweating, flushing, fever, leg pain, lethargy, palpitations, dependence edema, angina, rapid pulse, leg swelling, abnormal ECG, insomnia, drowsiness, migraine, vertigo, paresthesia, involuntary muscle contractions, sensory loss, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, colitis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disorders, gout, hyperlipidemia, diabetes, arthritis, arthralgia, leg numbness, anxiety, depression, neuroirritability, allergy, erectile dysfunction, lumbago, abdominal pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, abnormal liver function, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, edema, dizziness, headache, fatigue, weakness, vascular edema, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, dysuria, rhinitis, oropharyngeal discomfort, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, vascular edema, headache, dizziness, weakness, cough, nausea, fatigue, debility, lower extremity edema, facial edema, vascular edema, itching, hypersensitivity, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, elevated blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, lumbago, abdominal pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, abnormal liver function, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, headache, dizziness, edema, flushing, palpitations, insomnia, drowsiness, migraine, vertigo, paresthesia, involuntary muscle contractions, sensory loss, loss of appetite, constipation, dyspepsia, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia, allergic reaction, weakness, lumbago, burning sensation, lethargy, pain, stiffness, weight gain, weight loss, arthralgia, osteoarthritis, muscle cramps, myalgia, sexual dysfunction, insomnia, neuroirritability, depression, abnormal dreams, anxiety, depersonalization, vascular edema, erythema multiforme, itching, rash, erythematous rash, papular rash, visual disturbances, conjunctivitis, double vision, eye pain, tinnitus, ear pain, frequent urination, urination disorders, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, heart failure, irregular pulse, ectopic beats, skin depigmentation, dry skin, hair loss, dermatitis, muscle weakness, single contractions, coordination disorders, hypertonia, migraine, cold and clammy skin, apathy, amnesia, gastritis, increased appetite, loose stools, rhinitis, urination disorders, polyuria, abnormal olfaction, dysgeusia, abnormal ocular control, dry eye syndrome, gynecomastia, jaundice, elevated liver enzymes, leukopenia, confusion, exfoliative dermatitis, Stevens-Johnson syndrome, photosensitivity reaction, toxic epidermal necrolysis, vascular edema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, dysuria, rhinitis, oropharyngeal discomfort, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, vascular edema, headache, dizziness, weakness, cough, nausea, fatigue, debility, lower extremity edema, facial edema, vascular edema, itching, hypersensitivity, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, elevated blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, lumbago, abdominal pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, abnormal liver function, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not allow light in. Additionally, it is best to store the medication at room temperature between 1 and 30 degrees Celsius. This way, the efficacy of the medication can be maintained for a longer duration.

Appearance and packaging

Appearance

Bright pink oval film-coated tablets

Package unit

30 tablets (10 tablets x 3)/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.